Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 2:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,580 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus, Sudden-Onset Clear all
Completed Early Phase 1 Interventional

Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy

NCT01945099
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ePID closed loop system, hyaluronidase, Lispro-PH20
Device · Drug
Lead sponsor
Yale University
Other
Eligibility
12 Years to 40 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 15, 2026, 2:06 AM EDT
Completed Not applicable Interventional Results available

Accu-Chek® CONNECT at School (CATS) Pediatric Study

NCT02609633
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Accu-Chek® CONNECT DMS, DMS
Device
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
7 Years to 18 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
13
States / cities
Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 18, 2018 · Synced Oct 15, 2026, 2:06 AM EDT
Not yet recruiting Not applicable Interventional

Early Automated Insulin Delivery (AID) Pilot for Newly Diagnosed T1D

NCT07501338
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Tandem Automated Insulin Delivery System
Device
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 26 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 15, 2026, 2:06 AM EDT
Completed Phase 4 Interventional Results available

Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

NCT01269047
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pramlintide, Exenatide, Insulin
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
12 Years to 21 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Oct 15, 2026, 2:06 AM EDT
Completed Not applicable Interventional Results available

Improving Health Communication During the Transition From Pediatric to Adult Diabetes Care

NCT03734107
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Plan, Reflect, and Engage with Providers for Diabetes Care
Behavioral
Lead sponsor
Children's National Research Institute
Other
Eligibility
17 Years to 23 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 15, 2026, 2:06 AM EDT
Completed Not applicable Interventional

Artificial Pancreas With Different Stress Assessments in the Outpatient Setting

NCT04142229
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
iAPS, Sensor-Augmented Pump
Device · Other
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Santa Barbara, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 15, 2026, 2:06 AM EDT
Recruiting Not applicable Interventional

Automated Insulin for Management of Intrapartum Glycemia

NCT06883344
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Pregnancy, Pre-Gestational Diabetes
Interventions
Automated insulin delivery (AID) system, Intravenous (IV) insulin
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 15, 2026, 2:06 AM EDT
Terminated Phase 2 Interventional

Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis

NCT06007508
View directory record Official record
Conditions
DKA
Interventions
Insulin Glargine
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 15, 2026, 2:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

NCT07061574
View directory record Official record
Conditions
Type 1 Diabetes, New Onset
Interventions
Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
9 Years to 20 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
10
States / cities
San Francisco, California • New Haven, Connecticut • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 15, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C

NCT02383940
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 30 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Tustin, California • Aurora, Colorado • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 15, 2026, 2:06 AM EDT
Completed Not applicable Interventional

Supporting Parents of Young Children With Type 1 Diabetes in Closed-Loop System

NCT03354286
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Developmental & Technological Demands, Distress Reduction, Nutrition, Set Point, & C:I Ratio, Hypoglycemia management, Minimal Intervention
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 6 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 15, 2026, 2:06 AM EDT
Completed Not applicable Interventional Results available

A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use

NCT01464346
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
Enlite Sensor
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
Chula Vista, California • Escondido, California • La Jolla, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 15, 2026, 2:06 AM EDT
Completed Phase 3 Interventional

To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy

NCT01110746
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Viaject 7, LISPRO
Drug
Lead sponsor
Biodel
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Oct 15, 2026, 2:06 AM EDT
Completed Not applicable Interventional Results available

Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B

NCT00858273
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Antioxidant supplement, Diabetes treatment, Regular Insulin
Dietary Supplement · Other · Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 21 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 15, 2026, 2:06 AM EDT
Completed No phase listed Observational

Diabetic Kidney Alarm (DKA) Study

NCT03128229
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Diabetic Ketoacidosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
3 Years to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 15, 2026, 2:06 AM EDT
Completed Not applicable Interventional Results available

Sweetgoals for Type 1 Diabetes

NCT04646473
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Coaching, Incentives, Sweetgoals app
Behavioral
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
19 Years to 29 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Hanover, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 15, 2026, 2:06 AM EDT
Completed Not applicable Interventional

Early Feasibility Study of Zone-MPC and HMS With DiAs in the Outpatient Setting

NCT02463682
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
CGM and Insulin Pump, Closed-Loop Control System
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
Santa Barbara, California • Rochester, Minnesota • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 15, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Type 1 Diabetes Mellitus

NCT01481779
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Glargine, LY2605541, Insulin Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
Concord, California • Escondido, California • Fresno, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 15, 2026, 2:06 AM EDT
Not yet recruiting Not applicable Interventional

Can Mindfulness and Virtual Reality Reduce Stress in Young Adults With Type 1 Diabetes?

NCT07793097
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Mindfulness-Based Stress Reduction - Virtual Reality, Stress tip sheet
Behavioral · Other
Lead sponsor
Wayne State University
Other
Eligibility
16 Years to 20 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 15, 2026, 2:06 AM EDT
Completed No phase listed Observational

Use of CoG by Patients With Diabetes Mellitus

NCT03840161
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
non-invasive tissue glucose prediction
Device
Lead sponsor
Sciema UG
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 15, 2026, 2:06 AM EDT
Completed No phase listed Observational

Ability to Cope With Type 1 Diabetes

NCT00206362
View directory record Official record
Conditions
Depression
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
8 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 15, 2026, 2:06 AM EDT
Active, not recruiting Phase 2 Interventional

A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes

NCT04929379
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
Fenofibrate, Placebo
Drug · Other
Lead sponsor
Alessandro Doria
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Burlington, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 15, 2026, 2:06 AM EDT
Completed Not applicable Interventional Results available

Comparison of Glycemic Control Among Diabetics Using Three Different Pen Needles

NCT00928057
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
4mm x 32G pen needle, 8mm x 31G pen needle, 5mm x 31G pen needle
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Birmingham, Alabama • Escondido, California • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2010 · Synced Oct 15, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1

NCT01773707
View directory record Official record
Conditions
Abnormal Glucose Tolerance, Type 1 Diabetes
Interventions
CTLA4-Ig (Abatacept), Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years to 45 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
16
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 15, 2026, 2:06 AM EDT